Cerbios header

Cerbios header

X

[{"orgOrder":0,"company":"NHS England","sponsor":"Vertex Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Vertex Announces Expansion of Reimbursement Agreement With NHS England","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase IV","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"NHS England"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vertex Pharmaceuticals Reports Positive Phase 3 Study Results for TRIKAFTA\u00ae in People Ages 12 and Older With Cystic Fibrosis","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase IV","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"July 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Vertex Pharmaceuticals"},{"orgOrder":0,"company":"Biogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biogen to Initiate Phase 4 Respond Study Evaluating Benefit of Spinraza in Patients Treated with Zolgensma","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase IV","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"July 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Biogen"},{"orgOrder":0,"company":"Medexus Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Medexus Reaches 50% Enrollment in IXINITY\u00ae Phase 4 Clinical Trial Targeting Label Expansion for Pediatric Hemophilia B Patients","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase IV","country":"CANADA","productType":"Large molecule","productStatus":"Approved","date":"November 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Medexus Pharmaceuticals"},{"orgOrder":0,"company":"Biogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biogen Announces First Patient Treated in Respond Study Evaluating Benefit of Spinraza\u00ae in Patients Treated with Zolgensma\u00ae","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase IV","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"January 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"Biogen"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Interim Phase 4 Data Support TAKHZYRO\u00ae (lanadelumab) as an Effective Treatment to Reduce Attacks in Hereditary Angioedema Patients","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase IV","country":"JAPAN","productType":"Large molecule","productStatus":"Approved","date":"February 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Takeda Pharmaceutical"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Filters

×

FILTER:

filter

Company

filter

Sponsor

filter

Country

filter

Product Type

filter

News Type

Active Filter(s):

Filters

Reset Filter

All Developments

Product Type

Companies

Takeda Pharmaceutical

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Interim Phase 4 Data Support TAKHZYRO® (lanadelumab) as an Effective Treatment to Reduce Attacks in Hereditary Angioedema Patients

Details:

The observational Phase 4 EMPOWER study, evaluating real-world HAE attack rates before and after treatment with TAKHZYRO in patients with HAE types I and II, is ongoing. Full results of the EMPOWER study are expected to be published in 2024.

Lead Product(s): Lanadelumab

Therapeutic Area: Genetic Disease Product Name: Takhzyro

Highest Development Status: Phase IV Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable February 28, 2022

ASK
US

Upload
your Pipeline Activity

Biogen

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Biogen Announces First Patient Treated in Respond Study Evaluating Benefit of Spinraza® in Patients Treated with Zolgensma®

Details:

The RESPOND study aims to evaluate if Spinraza can benefit SMA patients who have experienced a ‘suboptimal’ response to Zolgensma (onasemnogene abeparvovec). It will be conducted at around 20 sites globally, with researchers aiming to enrol up to 60 children with SMA.

Lead Product(s): Nusinersen

Therapeutic Area: Genetic Disease Product Name: Spinraza

Highest Development Status: Phase IV Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 08, 2021

ASK
US

Upload
your Pipeline Activity

Medexus Pharmaceuticals

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Medexus Reaches 50% Enrollment in IXINITY® Phase 4 Clinical Trial Targeting Label Expansion for Pediatric Hemophilia B Patients

Details:

Medexus reached the 50% enrollment target in its Phase 4 clinical trial investigating IXINITY® as a prophylactic treatment for pediatric patients under 12 years of age with hemophilia B.

Lead Product(s): Recombinant coagulation factor IX

Therapeutic Area: Genetic Disease Product Name: Ixinity

Highest Development Status: Phase IV Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable November 16, 2020

ASK
US

Upload
your Pipeline Activity

Biogen

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Biogen to Initiate Phase 4 Respond Study Evaluating Benefit of Spinraza in Patients Treated with Zolgensma

Details:

The RESPOND study will seek to understand if the proven efficacy of SPINRAZA and its continuous production of SMN protein may also benefit patients previously treated with gene therapy.

Lead Product(s): Nusinersen

Therapeutic Area: Genetic Disease Product Name: Spinraza

Highest Development Status: Phase IV Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable July 21, 2020

ASK
US

Upload
your Pipeline Activity

Vertex Pharmaceuticals

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Vertex Pharmaceuticals Reports Positive Phase 3 Study Results for TRIKAFTA® in People Ages 12 and Older With Cystic Fibrosis

Details:

The results of this study demonstrate that the triple combination provides significant additional benefit compared to existing CFTR modulator therapy for F/G and F/RF patients and supports the benefit of the medicine for patients with at least one F508del mutation.

Lead Product(s): Ivacaftor,Tezacaftor,Elexacaftor

Therapeutic Area: Genetic Disease Product Name: Trikafta

Highest Development Status: Phase IV Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable July 20, 2020

ASK
US

Upload
your Pipeline Activity

NHS England

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Virtual Booth

Digital Content

Vertex Announces Expansion of Reimbursement Agreement With NHS England

Details:

As part of the agreement with NHS England, Vertex has committed to submit ORKAMBI®, SYMKEVI® and KAFTRIO® to the National Institute for Health and Care Excellence (NICE) within an agreed upon timetable, allowing for a period of real-world data collection on the medicines.

Lead Product(s): Ivacaftor,Tezacaftor,Elexacaftor

Therapeutic Area: Genetic Disease Product Name: Kaftrio

Highest Development Status: Phase IV Product Type: Small molecule

Partner/Sponsor/Collaborator: Vertex Pharmaceuticals

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Agreement June 30, 2020

ASK
US

Upload
your Pipeline Activity

POST ENQUIRY